Anti-inflammatory proteins and peptides and methods of preparation and use thereof
AssigneeManukamed Holdings Limited Partnership
InventorsKeryn Johnson, Cynthia Sun, Ulrike Hubl, Jaganmohan Billakanti
Life of this patent
Estimating the term…
Abstract
Anti-inflammatory proteins/peptides are described, as well as their uses, methods of preparation, and methods of their detection. Specifically described are major royal jelly proteins modified by methylglyoxal and fragments thereof from a Leptospermum derived honey and royal jelly.
Claims8
An isolated functional fragment of a major royal jelly protein (MRJP), which has anti-inflammatory capacity, which is not a naturally occurring functional fragment of a major royal jelly protein, and which includes up to 20 amino acids, wherein a lysine or arginine amino acid residue of the functional fragment has been chemically modified by methylglyoxal (MGO);
- and wherein:
- a. the functional fragment consists of the amino acid sequence:
- KISIHL (SEQ ID NO:
- 10);
- or
- b. the functional fragment comprises the peptide analogue:
- Ac-PFKISIHL-OH (SEQ ID NO:
- 19).
A wound dressing comprising a functional fragment of a major royal jelly protein (MRJP);
- wherein the functional fragment has anti-inflammatory capacity;
- wherein the functional fragment has been isolated, enriched, chemically synthesized, or recombinantly produced;
- the functional fragment including up to 20 amino acids;
- wherein a lysine or arginine amino acid residue of the functional fragment has been chemically modified by methylglyoxal (MGO);
- and wherein:
- a. the functional fragment consists of the amino acid sequence:
- KISIHL (SEQ ID NO:
- 10);
- or
- b. the functional fragment comprises the peptide analogue:
- Ac-PFKISIHL-OH (SEQ ID NO:
- 19).
A method of inhibiting Cathepsin B activity in a cellular tissue, comprising the step of contacting the cellular tissue with a functional fragment of a major royal jelly protein (MRJP);
- wherein the functional fragment has been isolated, enriched, synthesized, or recombinantly produced;
- and which includes up to 20 amino acids wherein a lysine or arginine amino acid residue of the functional fragment has been chemically modified by methylglyoxal (MGO);
- and wherein
- a. the functional fragment consists of the amino acid sequence
- KISIHL (SEQ ID NO:
- 10);
- or
- b. the functional fragment comprises the peptide analogue
- Ac-PFKISIHL-OH (SEQ ID NO:
- 19).
Dependencies are inferred from the claim text.